Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Alternative Molybdenum Source Could Surmount Isotope Shortage

By HospiMedica International staff writers
Posted on 03 Jan 2016
New technology for manufacturing molybdenum-99 (99Mo) without the need for a nuclear reactor could help break through the medical isotope bottleneck.

Developed by SHINE Medical Technologies (SHINE; Monona, WI, USA), the alternative production method involves bombarding a low enriched uranium (LEU) uranyl sulfate solution with fast neutrons generated by a linear accelerator at Argonne National Laboratory (ANL; Lemont, IL, USA). More...
The LEU then breaks down into hundreds of different isotopes, including 99Mo, which consists of 6% of the fissions created during the process. The 99Mo, which has a half-life of 2.75 days, must then be separated from the other fission products before it can be transported for use.

The half life of 99Mo is long compared to that of its daughter isotope, the radioactive tracer element technetium-99m (99mTc), which is created when 99Mo spontaneously decays through the release of a beta particle from its nucleus. The 99mTc, whose half-life is just six hours, is crucial for the sodium pertechnetate tracer produced using the GE Healthcare (GE, Little Chalfont, United Kingdom) Drytec generator. GE tested the new method by preparing two 99mTc-based radiopharmaceuticals, indicating the feasibility of the production method.

“We have been confident from the beginning that molybdenum-99 produced by our process would be compatible with existing technetium-99m generators, and now we’ve proved it,” said Greg Piefer, CEO of SHINE. “This demonstration validates that the cleaner, safer technical approach we’ve been pursuing can be fully integrated into the existing supply chain. I would like to thank GE and Argonne National Laboratory for making this test possible.”

“Our customers—clinics, hospitals and imaging specialists—rely on a secure supply of technetium-99m from molybdenum-99 to make sure that they can conduct important diagnostic imaging scans their patients need,” said Jan Makela, general manager of core imaging for GE Healthcare. “We are working hard to make this key isotope readily available and cost-effective for them.”

Because of its unstable nature, 99Mo does not occur naturally and is traditionally produced using highly enriched uranium (HEU) in research reactors. 99Mo is also not produced in the United States, leaving the country to rely on isotopes from other countries. SHINE is expected to begin commercial production in 2019 using this new process, and expects to be able to produce enough 99Mo to supply two-thirds of the demand of the United States.

Related Links:

SHINE Medical Technologies
Argonne National Laboratory
GE Healthcare



Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Biochip Array Technology
Evidence MultiSTAT Drugs of Abuse Urine Multiplex Panel
Surgical Dressing
ALLEVYN Ag+ SURGICAL
Gas Analyzer
GE SAM
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: Graphical Abstract (Aoibhin M. Sheedy et al., A replenishable peritoneal implant for localized delivery and peritoneal fluid sampling in ovarian cancer, Device (2026). DOI: 10.1016/j.device.2026.101050)

New Implant Provides Sustained Localized Therapy for Ovarian Cancer

Ovarian cancer is often diagnosed at advanced stages because symptoms such as bloating, pain, and pelvic pressure are nonspecific. Standard care relies on surgery and systemic therapy, yet tools for targeted... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.